李小婷

【摘要】 目的：探討依卡倍特钠、瑞巴派特分别联合四联疗法治疗幽门螺杆菌（Helicobacter pylori，Hp）阳性慢性萎缩性胃炎（chronic atrophic gastritis，CAG）患者的效果及安全性。方法：选取2018年6月-2019年12月本院收治的80例Hp阳性的慢性萎缩性胃炎患者为研究对象，根据治疗方案分为对照组与观察组，各40例。对照组应用瑞巴派特联合四联疗法治疗，观察组采用依卡倍特钠联合四联疗法治疗。对比两组治疗效果及不良反应发生率、胃蛋白酶水平变化及炎性反应因子水平变化。结果：两组治疗总有效率比较，差异无统计学意义（P>0.05）。观察组不良反应发生率低于对照组，差异有统计学意义（P<0.05）。治疗后，两组胃蛋白酶Ⅰ、胃蛋白酶Ⅱ水平均有所上升，且观察组胃蛋白酶Ⅰ、胃蛋白酶Ⅱ水平均高于对照组，差异均有统计学意义（P<0.05）。治疗后，两组IL-6、CRP及TNF-α水平与治疗前比均下降，且观察组IL-6、CRP水平均低于对照组，差异均有统计学意义（P<0.05），两组TNF-α水平比较，差异无统计学意义（P>0.05）。结论：依卡倍特钠、瑞巴派特分别联合四联疗法治疗Hp阳性CAG患者均取得较好的效果，能够有效增强胃黏膜分泌功能，提高胃蛋白酶水平，抑制炎症反应发展，从而改善患者临床症状，但依卡倍特钠联合四联疗法的不良反应发生率更低，安全性更高，值得临床研究与应用。

【关键词】 慢性萎缩性胃炎 幽门螺杆菌 四联疗法 瑞巴派特 依卡倍特钠

Efficacy and Safety of Ecabet Sodium and Rebamipide Combined with Quadruple Therapy in the Treatment of Helicobacter Pylori Positive Chronic Atrophic Gastritis/LI Xiaoting. //Medical Innovation of China， 2021， 18（05）： 0-040

[Abstract] Objective： To investigate the efficacy and safety of Ecabet Sodium and Rebamipide combined with quadruple therapy in the treatment of helicobacter pylori （Hp） positive chronic atrophic gastritis （CAG） patients. Method： A total of 80 patients with Hp positive CAG admitted to our hospital from June 2018 to December 2019 were selected as the research objects， they were divided into control group and observation group according to the treatment plan， 40 cases in each group. The control group was treated with Rebamipide combined with quadruple therapy， the observation group was treated with Ecabet Sodium combined with quadruple therapy. The therapeutic effect， the incidence of adverse reactions， the changes of pepsin levels and inflammatory reaction factors in the two groups were compared. Result： There was no significant difference in the total effective rate between the two groups （P>0.05）. The incidence of adverse reactions in the observation group was lower than that in the control group， the difference was statistically significant （P<0.05）. After treatment， two groups of pepsin Ⅰ， pepsin Ⅱ levels increased， the observation group of pepsin Ⅰ， pepsin Ⅱ levels were higher than those in the control group， the differences were statistical significance （P<0.05）. After treatment， the levels of IL-6， CRP and TNF-α in the two groups decreased compared with those before treatment， the levels of IL-6 and CRP in the observation group were lower than those in the control group， the differences were statistically significant （P<0.05）; there was no statistically significant difference in the level of TNF -α between the two groups （P>0.05）. Conclusion： Ecabet Sodium and Rebamipide respectively joint quadruple therapy to treat patients with helicobacter pylori positive the CAG achieved good curative effect， can effectively strengthen the function of gastric mucosa secretion， improve the level of pepsin， restrain development of inflammation， thus improving the clinical symptoms， but the Ecabet Sodium joint of quadruple therapy lower incidence of adverse reactions， higher security， worthy of clinical research and application.

[Key words] Chronic atrophic gastritis Helicobacter pylori Quadruple therapy Rebamipide Ecabet Sodium

First-authors address： Yangchun Peoples Hospital， Yangchun 529600， China

doi：10.3969/j.issn.1674-4985.2021.05.010

在临床上慢性萎缩性胃炎（chronic atrophic gastritis，CAG）是常见的内科疾病，主要是由于胃黏膜腺体及上皮出现萎缩性变化所致，严重影响到人们的日常生活与身心健康[1]。CAG多与人体免疫系统、幽门螺杆菌（Helicobacter pylori，Hp）等因素存在密切联系[2]，当受到Hp感染后，病情会不断进展，若不及时进行有效干预，会发展成癌前病变，严重可致胃癌。临床上常采用常规四联疗法治疗CAG，常规四联疗法有保护患者胃黏膜[3]，抗感染等作用，但综合治疗效果并不理想，因此联合其他药物共同治疗成为相关领域的研究新方向。依卡……